A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Naval Guastad Daver, Pau Montesinos, Daniel J. DeAngelo, Eunice S. Wang, Elisabetta Todisco, Corrado Tarella, Giovanni Martinelli, Harry Paul Erba, Eric Deconinck, Kendra L Sweet, Roland B. Walter, Moshe Yair Levy, Naveen Pemmaraju, Andrew A. Lane, David Rizzieri, Marina Konopleva, Callum Mortimer Sloss, Jiuzhou Wang, Kara E Malcolm, Patrick A Zweidler-McKay
Institutions: The University of Texas MD Anderson Cancer Center, Hospital Universitari i Politècnic La Fe, Dana-Farber Cancer Institute, Roswell Park Comprehensive Cancer Center, European Institute of Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Duke University, Centre Hospitalier Universitaire de Besançon, Moffitt Cancer Center, Fred Hutch Cancer Center, Duke Medical Center, ImmunoGen (United States)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3029398810